Last reviewed · How we verify
GXNPC1
At a glance
| Generic name | GXNPC1 |
|---|---|
| Also known as | hADSCs |
| Sponsor | Gwo Xi Stem Cell Applied Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Open-labeled Phase II Study to Evaluate the Efficacy and Safety of GXNPC-1 in Patients with Chronic Stroke (PHASE2)
- Clinical Trial Study About Human Adipose-Derived Stem Cells in the Stroke (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GXNPC1 CI brief — competitive landscape report
- GXNPC1 updates RSS · CI watch RSS
- Gwo Xi Stem Cell Applied Technology Co., Ltd. portfolio CI